# Cross Country Healthcare and Florida Atlantic University’s Christine E. Lynn College of Nursing Release Purpose Under Pressure: The State of Nursing in 2026
Canonical URL: https://biopharmsignal.com/news/CCRN/cross-country-healthcare-and-florida-atlantic-university-s-christine-e-lynn-college-of-nursing-release-purpose-under-pressure-the-state-of-nursing-in-2026
Ticker: CCRN
Company: Cross Country Healthcare
Source: Cross Country Healthcare
Published: 2026-05-05 11:00 EST
Original Source URL: https://ir.crosscountryhealthcare.com
## Summary

Fifth annual survey finds nurses remain deeply committed to patient care as workforce expectations, flexibility needs and support priorities continue to evolve BOCA RATON, Fla. --(BUSINESS WIRE)--May 5, 2026-- Cross Country Healthcare (NASDAQ: CCRN), a market-leading provider of workforce solutions

## Article Body
Fifth annual survey finds nurses remain deeply committed to patient care as workforce expectations, flexibility needs and support priorities continue to evolve BOCA RATON, Fla. --(BUSINESS WIRE)--May 5, 2026-- Cross Country Healthcare (NASDAQ: CCRN), a market-leading provider of workforce solutions
## Recent Company News
- 2026-05-14 11:30 EST — [Cross Country Expands AI-Powered Workforce Intelligence for Health Systems Through Exclusive Optimé Solution](https://biopharmsignal.com/news/CCRN/cross-country-expands-ai-powered-workforce-intelligence-for-health-systems-through-exclusive-optime-solution) — Source: Cross Country Healthcare
- 2026-05-07 20:15 EST — [Cross Country Healthcare Announces First Quarter 2026 Financial Results](https://biopharmsignal.com/news/CCRN/cross-country-healthcare-announces-first-quarter-2026-financial-results) — Source: Cross Country Healthcare
- 2026-05-06 21:32 EST — [Cross Country Healthcare to be Acquired by Knox Lane in All-Cash Transaction Valued at $437 Million](https://biopharmsignal.com/news/CCRN/cross-country-healthcare-to-be-acquired-by-knox-lane-in-all-cash-transaction-valued-at-437-million) — Source: Cross Country Healthcare
- 2026-05-05 11:00 EST — [Cross Country Healthcare and Florida Atlantic University’s Christine E. Lynn College of Nursing Release Purpose Under Pressure: The State of Nursing in 2026](https://biopharmsignal.com/news/CCRN/cross-country-healthcare-and-florida-atlantic-university-s-christine-e-lynn-college-of-nursing-release-purpose-under-pressure-the-state-of-nursing-in-2026) — Source: Cross Country Healthcare
- 2026-04-28 11:30 EST — [Cross Country Healthcare Marks 40 Years, Accelerates Next Generation of Workforce Intelligence and Orchestration](https://biopharmsignal.com/news/CCRN/cross-country-healthcare-marks-40-years-accelerates-next-generation-of-workforce-intelligence-and-orchestration) — Source: Cross Country Healthcare
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)